CAR T-cell therapy for blood cancers may provide long-term remission for some patients, but their clinical benefit is limited by the complexity and cost of manufacturing and lack of efficacy in solid tumors. New developments in the field, however, offer hope to patients of greater...
Our articles provide quick read summaries to help keep you informed and looking forward with industry insights.